ClinicalTrials.gg
CompletedNCT04048343NOZOMIUpdated Jun 1, 2022Results posted

Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma

A Phase 3 interventional study of Biological: Experimental: Tezepelumab in Severe Asthma, sponsored by AstraZeneca. Completed at 5 sites in Japan. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
19th of 28
65 · median 121
Started
2019
with 4 others
Phase 3
16 of 28
4 open now
Registered
11th of 28
by date
Lead sponsor
16 of 28
AstraZeneca

Among the 28 studies testing tezepelumab in Asthma, this one is the 19th largest by enrollment, is one of 5 that started in 2019, is one of 16 in phase 3, and was the 11th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

This is an open-label, single arm study designed to evaluate the safety of tezepelumab administered subcutaneously every 4 weeks in Japanese adult and adolescent subjects with inadequately controlled severe asthma.

Read the detailed description

This is open-label, single arm study designed to evaluate the safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 66 subjects will be dosed in Japan. Subjects will receive tezepelumab administered via subcutaneous injection at the study site, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks.

03

Conditions studied

  • Severe Asthma

Browse trials for

Keywords

  • Asthma
  • Uncontrolled Asthma
  • Severe Uncontrolled Asthma
04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age. 12-80 Documented physician-diagnosed asthma for at least 12 months Subjects who have received a physician-prescribed asthma controller medication with medium or high dose ICS for at least 12 months.

Documented treatment with a total daily dose of either medium or high dose ICS (≥ 500 µg fluticasone propionate dry powder formulation equivalent total daily dose) for at least 3 months.

At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.

Documented history of at least 1 asthma exacerbation events within 12 months. ACQ-6 score ≥1.5 at screening or on day of registration.

Exclusion criteria

Exclusion Criteria:

Pulmonary disease other than asthma. History of cancer. History of a infection. Current smokers or subjects with smoking history ≥10 pack-yrs. History of chronic alcohol or drug abuse within 12 months. , C or . Pregnant or breastfeeding. History of anaphylaxis following any biologic therapy. Subject randomized in the current study or previous tezepelumab studies

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Tezepelumab

    Tezepelumab: Tezepelumab subcutaneous injection

    Drug: Biological: Experimental: Tezepelumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Events

    The number of subjects who experienced an AE during on-treatment period was summarised.

    Time frame: From first dose of study drug until last study visit at Week 64

07

Results

Posted Jun 1, 2022

Participant flow

A total of 65 subjects fulfilled all inclusion and exclusion criteria and were registered to receive treatment at 5 centres in Japan.

Participant flow — Overall Study
MilestoneTezepelumab 210mg Q4W
Started65
Completed65
Not completed0

Outcome measures

PrimaryNumber of Subjects With Adverse Events

The number of subjects who experienced an AE during on-treatment period was summarised.

Time frame:
From first dose of study drug until last study visit at Week 64
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events
ParticipantsTezepelumab 210 Q4W
Number of Subjects With Adverse Events39

Adverse events

Collected over From first dose of study drug until last study visit at Week 64. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tezepelumab 210mg Q4W0/65 (0%)4/65 (6.2%)29/65 (44.6%)
Most frequent serious events
Most frequent serious events
EventTezepelumab 210mg Q4W
Atrial fibrillationCardiac disorders1/65
Gastroenteritis viralInfections and infestations1/65
Lung abscessInfections and infestations1/65
TonsillitisInfections and infestations1/65
Most frequent other events
Showing 10 of 15
Most frequent other events
EventTezepelumab 210mg Q4W
NasopharyngitisInfections and infestations13/65
PharyngitisInfections and infestations6/65
Herpes zosterInfections and infestations3/65
ContusionInjury, poisoning and procedural complications3/65
Back painMusculoskeletal and connective tissue disorders3/65
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders3/65
Injection site erythemaGeneral disorders2/65
BronchitisInfections and infestations2/65
GastroenteritisInfections and infestations2/65
Oral herpesInfections and infestations2/65

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tezepelumab 210mg Q4W
<=18 years1
Between 18 and 65 years52
>=65 years12
Age, Continuous
Age, Continuous(Years)Tezepelumab 210mg Q4W
Mean51.3 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)Tezepelumab 210mg Q4W
Female33
Male32
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tezepelumab 210mg Q4W
White0
Black or African American0
Asian65
Native Hawaiian or Other Pacific Islander0
American Indian or Alaska Native0
Other0
08

Study locations

5 sites
  • Research Site
    Chuo-ku, 103-0022, Japan
  • Research Site
    Chuo-ku, 104-0031, Japan
  • Research Site
    Sagamihara-shi, 228-0815, Japan
  • Research Site
    Shinagawa-ku, 140-8522, Japan
  • Research Site
    Shinjuku-ku, 169-0073, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Mar 2021, 21 months.

Results were first posted in Jun 2022, 1 year 2 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 21 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2019
First posted
Aug 7, 2019
StartActual
Jun 10, 2019
Primary completionActual
Mar 18, 2021
CompletionActual
Mar 18, 2021
Results first posted
Jun 1, 2022
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04048343
Lead sponsor
AstraZeneca
Collaborators
Amgen
Responsible party
Sponsor
First posted
Aug 7, 2019
Start date
Jun 10, 2019
Primary completion
Mar 18, 2021
Completion
Mar 18, 2021
Results posted
Jun 1, 2022
Last update
Jun 1, 2022

Study contacts

Masaharu Shinkai, MD
principal investigator · Tokyo Shinagawa Hospital Medical Corporation Association, Japan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion